Cell Replacement Therapy Improves Pathological Hallmarks in a Mouse Model of Leukodystrophy Vanishing White Matter

Stem Cell Reports. 2019 Mar 5;12(3):441-450. doi: 10.1016/j.stemcr.2019.01.018. Epub 2019 Feb 21.

Abstract

Stem cell therapy has great prospects for brain white matter disorders, including the genetically determined disorders called leukodystrophies. We focus on the devastating leukodystrophy vanishing white matter (VWM). Patients with VWM show severe disability and early death, and treatment options are lacking. Previous studies showed successful cell replacement therapy in rodent models for myelin defects. However, proof-of-concept studies of allogeneic cell replacement in models representative of human leukodystrophies are lacking. We tested cell replacement in a mouse model representative of VWM. We transplanted different murine glial progenitor cell populations and showed improved pathological hallmarks and motor function. Improved mice showed a higher percentage of transplanted cells that differentiated into GFAP+ astrocytes, suggesting best therapeutic prospects for replacement of astroglial lineage cells. This is a proof-of-concept study for cell transplantation in VWM and suggests that glial cell replacement therapy is a promising therapeutic strategy for leukodystrophy patients.

Keywords: astrocytes; cell replacement therapy; glial cells; leukodystrophy; oligodendrocytes; stem cells; vanishing white matter; white matter disorder.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Astrocytes / pathology
  • Cell Differentiation / physiology
  • Cell- and Tissue-Based Therapy / methods
  • Disease Models, Animal
  • Female
  • Humans
  • Leukoencephalopathies / pathology*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Myelin Sheath / pathology
  • Neuroglia / pathology
  • Stem Cell Transplantation / methods
  • Stem Cells / pathology
  • White Matter / pathology*